One of many business successes that came out of this week's AACC show and Clinical Lab Expo was the deal renewed by Siemens Healthcare Diagnostics and Sysmex Corp. till 2018. The two companies have announced the signing of a five-year global supply, distributorship, sales, and service contract extension under which clinical laboratory customers around the world can retain access to a large portfolio of hemostasis instruments and reagents. The companies, which began partnering in 1995, also agreed to continue joint product development activities, ensuring customer access to new hemostasis technology. The signing occurred during the 2012 AACC and ASCLS Annual Meetings and Clinical Lab Expo this week in Los Angeles.
The large assortment of hemostasis products covered in this latest agreement is used by clinical laboratories to test for blood disorders in patients and to monitor patients on blood-thinning medication. To date, Sysmex and Siemens have released to market a variety of advanced solutions, including the recently launched Sysmex CS-5100, the top-end model in Sysmex's CS hemostasis analyzer series; the Sysmex CA-600 Systems, a new line of compact, fully automated hemostasis analyzers; as well as several new Siemens Innovance reagents.
"We are pleased to extend our longstanding relationship with Siemens Healthcare Diagnostics," said Hisashi Ietsugu, President and CEO of Sysmex Corp. "Our partnership in the field of hemostasis combines the strength of two leading diagnostics companies whose joint expertise offers best-in-class solutions to the laboratory. We remain committed to further expand our offerings with enhanced clinical utility and workflow efficiency."
"Our shared goal to deliver high-quality products and services that address our customers' needs is a key reason for the success of our 17-year relationship," said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. "Sysmex and Siemens remains a reliable partnership for customers worldwide amidst an evolving hemostasis market. Together, we will continue offering customers the broad portfolio of hemostasis solutions they have come to expect from us and we will also focus on delivering next-generation technologies going forward."